Work

Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.4_suppl.412

Authors: Stephen Michael Keefe, Daniel Heitjan, Meliessa Hennessey, Janelle Robinson, Kristine Mykulowicz, Amy Marshall, Orvar Gunnarsson, Ronac Mamtani, David J. Vaughn, Jean H. Hoffman-Censits, Katherine L. Nathanson, Priti Lal, Daniel A. Pryma, Scott Eliasof, Edward Graeme Garmey, Roger B. Cohen, Naomi B. Haas

Institutions: Abramson Cancer Center, University of Pennsylvania, Cerulean Pharma (United States), Thomas Jefferson University, Sidney Kimmel Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591350607

Cites:

Cited by: 4

Related to: 10